Delving into the Latest Updates on AC-203 (Accro Bioscience) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

IK X, IK-X

+ [1]

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesInfectious DiseasesNervous System Diseases+ [3]

Active Indication

Alzheimer DiseaseAnemia, AplasticAnkylosing Spondylitis+ [3]

Inactive Indication-

Originator Organization

Accro Bioscience (Suzhou) Co., Ltd.Startup

Active Organization

Accro Bioscience (Suzhou) Co., Ltd.Startup

Inactive Organization-

Drug Highest PhaseIND Application

First Approval Date-

Regulation-

Login to view timeline

In order to assess the response of plasma biochemical parameters to anaesthesia, 40 New Zealand White (NZW) rabbits were assigned to four treatment groups ( n = 10): control (1 ml i.v. saline solution), fentanyl-droperidol (FD) (0.4 ml/kg s.c. of 'thalamonal' solution; 2.5 mg/ml droperidol, 0.05 mg/ml fentanyl), ketamine (K) (10 mg/kg i.v.) with either xylazine (X) (3 mg/kg i.v.) or diazepam (D) (2 mg/kg i.v.). Blood samples were obtained from the central ear artery at six time points: before injection, and at 10, 30, 60, 120 min and 24 h after injection of the anaesthetics/saline. Plasma ALT, AST, ALP, GGT, BUN, creatinine, phosphate and potassium levels were measured by the Hitachi 747 autoanalyser. The administration of K-X increased ( P < 0.05) plasma ALT (from 11.4 ± 0.9 to 20.2 ± 1.7 IU/l, at 10 min), AST (from 10.5 ± 3.3 to 34 ± 2.1 IU/l, at 120 min), BUN (from 17.2 ± 0.9 to 25.8 ± 1.8 mg/dl, at 60 min) and creatinine concentrations (from 1 ± 0.1 to 1.6 ± 0.2 mg/dl, at 10 min). After K-D administration, we observed an increase ( P < 0.05) in plasma ALT (from 11.4 ± 0.9 to 20.2 ± 1.1 IU/l, at 10 min), AST (from 11.4 ± 1.6 to 28 ± 3.7 IU/l, at 10 min), BUN (from 15.8 ± 0.8 to 30 ± 1.5 mg/dl, at 10 min) and creatinine levels (from 1 ± 0.08 to 2.2 ± 0.2 mg/dl, at 120 min). No significant changes were seen in the FD group. We conclude that K-X and K-D may affect plasma concentration of select serum enzymes and biochemical parameters. These results should be taken into account when blood samples are evaluated in treated rabbits.

100 Deals associated with AC-203 (Accro Bioscience)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	IND Application	CN	Accro Bioscience (Suzhou) Co., Ltd.Startup	-
Anemia, Aplastic	IND Application	CN	Accro Bioscience (Suzhou) Co., Ltd.Startup	-
Ankylosing Spondylitis	IND Application	CN	Accro Bioscience (Suzhou) Co., Ltd.Startup	-
Hidradenitis Suppurativa	IND Application	CN	Accro Bioscience (Suzhou) Co., Ltd.Startup	-
Rheumatoid Arthritis	IND Application	CN	Accro Bioscience (Suzhou) Co., Ltd.Startup	-
Systemic Lupus Erythematosus	IND Application	CN	Accro Bioscience (Suzhou) Co., Ltd.Startup	-